Daniel N. Bracey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel N. Bracey has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Thomas L. Smith
Division of Orthopaedic Surgery Wake Forest Baptist Medical Center Winston‐Salem NC USA
4 shared publications- Alexander H. Jinnah
Wake Forest School of Medicine
3 shared publications Patrick W. Whitlock
Division of Orthopaedic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
3 shared publicationsAlexander H. Jinnah
Department of Orthopaedic Surgery, Wake Forest School of Medicine, Winston-Salem, NC, USA
2 shared publicationsCynthia L. Emory
Division of Orthopaedic Surgery Wake Forest Baptist Medical Center Winston‐Salem NC USA
2 shared publicationsJeffrey S. Willey
Department of Radiation/Oncology Wake Forest Baptist Medical Center Winston‐Salem NC USA
2 shared publications
Latest Publications
- Open Access
- 22 August 2022
- Published by Wiley in Aging Cell
- Vol. 21 (9) , e13698
Comet assay for quantification of the increased DNA damage burden in primary human chondrocytes with aging and osteoarthritis
It is known that chondrocytes from joints with osteoarthritis (OA) exhibit high levels of DNA damage, but the degree to which chondrocytes accumulate DNA damage during “normal aging” has not been established. The goal of this study was to quantify the DNA damage present in chondrocytes obtained from cadaveric donors of a wide age range, and to compare the extent of this damage to OA chondrocytes. The alkaline comet assay was used to measure the DNA damage in normal cartilage from the ankle (talus) and the knee (femur) of cadaveric donors, as well as in OA chondrocytes obtained at the time of total knee replacement. Chondrocytes from younger donors (70 years) as assessed by the percentage of DNA in the comet “tail”. In donors between 50 and 60 years old, there was increased DNA damage in chondrocytes from OA cartilage as compared to cadaveric. Talar chondrocytes from 23 donors between the ages of 34 and 78 revealed a linear increase in DNA damage with age (R2 = 0.865, p < 0.0001). A “two‐tailed” comet assay was used to demonstrate that most of the accumulated damage is in the form of strand breaks as opposed to alkali‐labile base damage. Chondrocytes from young donors required 10 Gy irradiation to recapitulate the DNA damage present in chondrocytes from older donors. Given the potential for DNA damage to contribute to chondrocyte dysfunction and senescence, this study supports the investigation of mechanisms by which hypo‐replicative cell types accumulate high levels of damage.
- 22 August 2022
- Published by Wiley in Aging Cell
- Vol. 21 (9) , e13698
Open AccessComet assay for quantification of the increased DNA damage burden in primary human chondrocytes with aging and osteoarthritis
It is known that chondrocytes from joints with osteoarthritis (OA) exhibit high levels of DNA damage, but the degree to which chondrocytes accumulate DNA damage during “normal aging” has not been established. The goal of this study was to quantify the DNA damage present in chondrocytes obtained from cadaveric donors of a wide age range, and to compare the extent of this damage to OA chondrocytes. The alkaline comet assay was used to measure the DNA damage in normal cartilage from the ankle (talus) and the knee (femur) of cadaveric donors, as well as in OA chondrocytes obtained at the time of total knee replacement. Chondrocytes from younger donors (70 years) as assessed by the percentage of DNA in the comet “tail”. In donors between 50 and 60 years old, there was increased DNA damage in chondrocytes from OA cartilage as compared to cadaveric. Talar chondrocytes from 23 donors between the ages of 34 and 78 revealed a linear increase in DNA damage with age (R2 = 0.865, p < 0.0001). A “two‐tailed” comet assay was used to demonstrate that most of the accumulated damage is in the form of strand breaks as opposed to alkali‐labile base damage. Chondrocytes from young donors required 10 Gy irradiation to recapitulate the DNA damage present in chondrocytes from older donors. Given the potential for DNA damage to contribute to chondrocyte dysfunction and senescence, this study supports the investigation of mechanisms by which hypo‐replicative cell types accumulate high levels of damage.
- 1 January 2022
- Published by Springer Nature
- p. 335-356
Fixed- Versus Mobile-Bearing Total Knee Arthroplasty
- 1 January 2022
- Published by Springer Nature
- p. 335-356
Fixed- Versus Mobile-Bearing Total Knee Arthroplasty
- 26 November 2020
- Published by Wiley in Xenotransplantation
- Vol. 28 (2) , e12662
Improved osseointegration using porcine xenograft compared to demineralized bone matrix for the treatment of critical defects in a small animal model
Background: Autograft (AG) is the gold standard bone graft due to biocompatibility, osteoconductivity, osteogenicity, and osteoinductivity. Alternatives include allografts and xenografts (XG).Methods: We investigated the osseointegration and biocompatibility of a decellularized porcine XG within a critical defect animal model. We hypothesized that the XG will result in superior osseointegration compared to demineralized bone matrix (DBM) and equivalent immune response to AG. Critical defects were created in rat femurs and treated with XG, XG plus bone morphogenetic protein (BMP)‐2, DBM, or AG. Interleukin (IL)‐2 and IFN‐gamma levels (inflammatory markers) were measured from animal blood draws at 1 week and 1 month post‐operatively. At 1 month, samples underwent micro‐positron‐emission tomography (microPET) scans following 18‐NaF injection. At 16 weeks, femurs were retrieved and sent for micro‐computerized tomography (microCT) scans for blinded grading of osseointegration or were processed for histologic analysis with tartrate resistant acid phosphatase (TRAP) and pentachrome.Results: Enzyme linked immunosorbent assay testing demonstrated greater IL‐2 levels in the XG vs. AG 1 week post‐op; which normalized by 28 days post‐op. MicroPET scans showed increased uptake within the AG compared to all groups. XG and XG + BMP‐2 showed a trend toward increased uptake compared with DBM. MicroCT scans demonstrated increased osseointegration in XG and XG + BMP groups compared to DBM. Pentachrome staining demonstrated angiogenesis and endochondral bone formation. Furthermore, positive TRAP staining in samples from all groups indicated bone remodeling.Conclusions: These data suggest that decellularized and oxidized porcine XG is biocompatible and at least equivalent to DBM in the treatment of a critical defect in a rat femur model.
- 26 November 2020
- Published by Wiley in Xenotransplantation
- Vol. 28 (2) , e12662
Improved osseointegration using porcine xenograft compared to demineralized bone matrix for the treatment of critical defects in a small animal model
Background: Autograft (AG) is the gold standard bone graft due to biocompatibility, osteoconductivity, osteogenicity, and osteoinductivity. Alternatives include allografts and xenografts (XG).Methods: We investigated the osseointegration and biocompatibility of a decellularized porcine XG within a critical defect animal model. We hypothesized that the XG will result in superior osseointegration compared to demineralized bone matrix (DBM) and equivalent immune response to AG. Critical defects were created in rat femurs and treated with XG, XG plus bone morphogenetic protein (BMP)‐2, DBM, or AG. Interleukin (IL)‐2 and IFN‐gamma levels (inflammatory markers) were measured from animal blood draws at 1 week and 1 month post‐operatively. At 1 month, samples underwent micro‐positron‐emission tomography (microPET) scans following 18‐NaF injection. At 16 weeks, femurs were retrieved and sent for micro‐computerized tomography (microCT) scans for blinded grading of osseointegration or were processed for histologic analysis with tartrate resistant acid phosphatase (TRAP) and pentachrome.Results: Enzyme linked immunosorbent assay testing demonstrated greater IL‐2 levels in the XG vs. AG 1 week post‐op; which normalized by 28 days post‐op. MicroPET scans showed increased uptake within the AG compared to all groups. XG and XG + BMP‐2 showed a trend toward increased uptake compared with DBM. MicroCT scans demonstrated increased osseointegration in XG and XG + BMP groups compared to DBM. Pentachrome staining demonstrated angiogenesis and endochondral bone formation. Furthermore, positive TRAP staining in samples from all groups indicated bone remodeling.Conclusions: These data suggest that decellularized and oxidized porcine XG is biocompatible and at least equivalent to DBM in the treatment of a critical defect in a rat femur model.
- 5 May 2020
- Published by Wiley in Xenotransplantation
- Vol. 27 (5) , e12600
Bone xenotransplantation: A review of the history, orthopedic clinical literature, and a single‐center case series
Background: One‐half of all orthopedic surgeries require bone grafting for successful outcomes in fusions, reconstructive procedures, and the treatment of osseous defects resulting from trauma, tumor, infection, or congenital deformity. Autologous bone grafts are taken from the patient's own body and remain the “gold standard” graft choice but are limited in supply and impart significant patient morbidity. Xenograft bone is an attractive alternative from donors with controlled biology, in large supply and at a theoretically lower cost. Clinical results with xenograft bone for orthopedic applications have been mixed in the limited clinical trials published.Methods: In the current review, we introduce fundamental principles of bone grafting, systematically review all orthopedic clinical studies reporting outcomes on patients transplanted with xenograft bone, and we present our own clinical results from patients grafted with bovine bone in foot and ankle reconstructive procedures.Results: Thirty‐one clinical studies were identified for review and the majority (47%) were from spine surgery literature. Favorable results were reported in 44% of studies while 47% of studies reported poor outcomes and discouraged use of xenograft bone products. In our own clinical series, xenograft failed to integrate with host bone in 58% of cases and persistent pain was reported in 83% of cases. Conclusions: This is the first systematic review of clinical results reported after bone xenotransplantation for orthopaedic surgery applications. Current literature does not support the use of xenograft bone products and our institution’s results are consistent with this conclusion. Our laboratory has reported promising pre‐clinical results with a xenograft product derived from porcine cancellous bone, but additional testing is required before considering clinical translation.
- 5 May 2020
- Published by Wiley in Xenotransplantation
- Vol. 27 (5) , e12600
Bone xenotransplantation: A review of the history, orthopedic clinical literature, and a single‐center case series
Background: One‐half of all orthopedic surgeries require bone grafting for successful outcomes in fusions, reconstructive procedures, and the treatment of osseous defects resulting from trauma, tumor, infection, or congenital deformity. Autologous bone grafts are taken from the patient's own body and remain the “gold standard” graft choice but are limited in supply and impart significant patient morbidity. Xenograft bone is an attractive alternative from donors with controlled biology, in large supply and at a theoretically lower cost. Clinical results with xenograft bone for orthopedic applications have been mixed in the limited clinical trials published.Methods: In the current review, we introduce fundamental principles of bone grafting, systematically review all orthopedic clinical studies reporting outcomes on patients transplanted with xenograft bone, and we present our own clinical results from patients grafted with bovine bone in foot and ankle reconstructive procedures.Results: Thirty‐one clinical studies were identified for review and the majority (47%) were from spine surgery literature. Favorable results were reported in 44% of studies while 47% of studies reported poor outcomes and discouraged use of xenograft bone products. In our own clinical series, xenograft failed to integrate with host bone in 58% of cases and persistent pain was reported in 83% of cases. Conclusions: This is the first systematic review of clinical results reported after bone xenotransplantation for orthopaedic surgery applications. Current literature does not support the use of xenograft bone products and our institution’s results are consistent with this conclusion. Our laboratory has reported promising pre‐clinical results with a xenograft product derived from porcine cancellous bone, but additional testing is required before considering clinical translation.
- 25 July 2019
- Published by Wiley in Xenotransplantation
- Vol. 26 (5) , e12534
A porcine xenograft‐derived bone scaffold is a biocompatible bone graft substitute: An assessment of cytocompatibility and the alpha‐Gal epitope
Background: Xenografts are an attractive alternative to traditional bone grafts because of the large supply from donors with predictable morphology and biology as well as minimal risk of human disease transmission. Clinical series involving xenograft bone transplantation, most commonly from bovine sources, have reported poor results with frequent graft rejection and failure to integrate with host tissue. Failures have been attributed to residual alpha‐Gal epitope in the xenograft which humans produce natural antibody against. To the authors' knowledge, there is currently no xenograft‐derived bone graft substitute that has been adopted by orthopedic surgeons for routine clinical use.Methods: In the current study, a bone scaffold intended to serve as a bone graft substitute was derived from porcine cancellous bone using a tissue decellularization and chemical oxidation protocol. In vitro cytocompatibility, pathogen clearance, and alpha‐Gal quantification tests were used to assess the safety of the bone scaffold intended for human use.Results: In vitro studies showed the scaffold was free of processing chemicals and biocompatible with mouse and human cell lines. When bacterial and viral pathogens were purposefully added to porcine donor tissue, processing successfully removed these pathogens to comply with sterility assurance levels established by allograft tissue providers. Critically, 98.5% of the alpha‐Gal epitope was removed from donor tissue after decellularization as shown by ELISA inhibition assay and immunohistochemical staining.Conclusions: The current investigation supports the biologic safety of bone scaffolds derived from porcine donors using a decellularization protocol that meets current sterility assurance standards. The majority of the highly immunogenic xenograft carbohydrate was removed from donor tissue, and these findings support further in vivo investigation of xenograft‐derived bone tissue for orthopedic clinical application.
- 25 July 2019
- Published by Wiley in Xenotransplantation
- Vol. 26 (5) , e12534
A porcine xenograft‐derived bone scaffold is a biocompatible bone graft substitute: An assessment of cytocompatibility and the alpha‐Gal epitope
Background: Xenografts are an attractive alternative to traditional bone grafts because of the large supply from donors with predictable morphology and biology as well as minimal risk of human disease transmission. Clinical series involving xenograft bone transplantation, most commonly from bovine sources, have reported poor results with frequent graft rejection and failure to integrate with host tissue. Failures have been attributed to residual alpha‐Gal epitope in the xenograft which humans produce natural antibody against. To the authors' knowledge, there is currently no xenograft‐derived bone graft substitute that has been adopted by orthopedic surgeons for routine clinical use.Methods: In the current study, a bone scaffold intended to serve as a bone graft substitute was derived from porcine cancellous bone using a tissue decellularization and chemical oxidation protocol. In vitro cytocompatibility, pathogen clearance, and alpha‐Gal quantification tests were used to assess the safety of the bone scaffold intended for human use.Results: In vitro studies showed the scaffold was free of processing chemicals and biocompatible with mouse and human cell lines. When bacterial and viral pathogens were purposefully added to porcine donor tissue, processing successfully removed these pathogens to comply with sterility assurance levels established by allograft tissue providers. Critically, 98.5% of the alpha‐Gal epitope was removed from donor tissue after decellularization as shown by ELISA inhibition assay and immunohistochemical staining.Conclusions: The current investigation supports the biologic safety of bone scaffolds derived from porcine donors using a decellularization protocol that meets current sterility assurance standards. The majority of the highly immunogenic xenograft carbohydrate was removed from donor tissue, and these findings support further in vivo investigation of xenograft‐derived bone tissue for orthopedic clinical application.
- Open Access
Investigating the Osteoinductive Potential of a Decellularized Xenograft Bone Substitute
1. Bone grafting is the second most common tissue transplantation procedure worldwide. The gold standard for bone grafting is the autograft; however, due to morbidity and limited supply, new alternatives, including allograft and tissue-engineered bone substitutes, are needed to satisfy long-term demand. One of the most desired properties of tissue-engineered bone substitutes is osteoinductivity, defined as the ability to stimulate primitive cells to differentiate into a bone forming lineage. In the current study, we treated porcine bone with a decellularization protocol to produce a bone scaffold. We examined whether the scaffold possessed osteoinductive potential and could be used to create a tissue-engineered bone microenvironment. To test if the bone scaffold was a viable host, pre-osteoblasts were seeded, incubated in vitro , and analyzed for markers of osteogenic differentiation. To assess these properties in vivo , scaffolds with and without pre-osteoblasts pre-seeded were subcutaneously implanted in mice for four weeks. The scaffolds underwent micro-computed tomography (microCT) scanning before implantation. After retrieval, the scaffolds were analyzed for osteogenic differentiation or re-scanned by microCT to assess new bone formation with the subsequent histological assessment. The osteoinductive potential was observed in vitro with similar osteogenic markers being expressed as observed in demineralized bone matrix and significantly greater expression of these markers than controls. By microCT, paired t-tests demonstrated significantly increased bone volume:total volume (BV/TV) and trabecular thickness (Tb.Th) after explantation in all groups. Pentachrome staining demonstrated osteogenesis within the scaffold, and angiogenesis in the scaffold was confirmed by CD31 staining for blood vessels. These results demonstrate that porcine bone maintains its osteoinductive properties after the application of a novel decellularization and oxidation protocol. Future work must be performed to definitively prove osteogenesis of human mesenchymal stem cells, biocompatibility in large animal models, and osteoinduction/osseointegration in a relevant clinical model in vivo . The ability to create a functional bone microenvironment using decellularized xenografts will impact regenerative medicine, orthopaedic reconstruction, and could be used in the research of multiple diseases.
Open AccessInvestigating the Osteoinductive Potential of a Decellularized Xenograft Bone Substitute
1. Bone grafting is the second most common tissue transplantation procedure worldwide. The gold standard for bone grafting is the autograft; however, due to morbidity and limited supply, new alternatives, including allograft and tissue-engineered bone substitutes, are needed to satisfy long-term demand. One of the most desired properties of tissue-engineered bone substitutes is osteoinductivity, defined as the ability to stimulate primitive cells to differentiate into a bone forming lineage. In the current study, we treated porcine bone with a decellularization protocol to produce a bone scaffold. We examined whether the scaffold possessed osteoinductive potential and could be used to create a tissue-engineered bone microenvironment. To test if the bone scaffold was a viable host, pre-osteoblasts were seeded, incubated in vitro , and analyzed for markers of osteogenic differentiation. To assess these properties in vivo , scaffolds with and without pre-osteoblasts pre-seeded were subcutaneously implanted in mice for four weeks. The scaffolds underwent micro-computed tomography (microCT) scanning before implantation. After retrieval, the scaffolds were analyzed for osteogenic differentiation or re-scanned by microCT to assess new bone formation with the subsequent histological assessment. The osteoinductive potential was observed in vitro with similar osteogenic markers being expressed as observed in demineralized bone matrix and significantly greater expression of these markers than controls. By microCT, paired t-tests demonstrated significantly increased bone volume:total volume (BV/TV) and trabecular thickness (Tb.Th) after explantation in all groups. Pentachrome staining demonstrated osteogenesis within the scaffold, and angiogenesis in the scaffold was confirmed by CD31 staining for blood vessels. These results demonstrate that porcine bone maintains its osteoinductive properties after the application of a novel decellularization and oxidation protocol. Future work must be performed to definitively prove osteogenesis of human mesenchymal stem cells, biocompatibility in large animal models, and osteoinduction/osseointegration in a relevant clinical model in vivo . The ability to create a functional bone microenvironment using decellularized xenografts will impact regenerative medicine, orthopaedic reconstruction, and could be used in the research of multiple diseases.
- Open Access
- 12 July 2018
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 9 (3) , 45
A Decellularized Porcine Xenograft-Derived Bone Scaffold for Clinical Use as a Bone Graft Substitute: A Critical Evaluation of Processing and Structure
Background: Bone grafts are used in approximately one half of all musculoskeletal surgeries. Autograft bone is the historic gold standard but is limited in supply and its harvest imparts significant morbidity to the patient. Alternative sources of bone graft include allografts, synthetics and, less commonly, xenografts which are taken from animal species. Xenografts are available in unlimited supply from healthy animal donors with controlled biology, avoiding the risk of human disease transmission, and may satisfy current demand for bone graft products. Methods: In the current study, cancellous bone was harvested from porcine femurs and subjected to a novel decellularization protocol to derive a bone scaffold. Results: The scaffold was devoid of donor cellular material on histology and DNA sampling (p < 0.01). Microarchitectural properties important for osteoconductive potential were preserved after decellularization as shown by high resolution imaging modalities. Proteomics data demonstrated similar profiles when comparing the porcine bone scaffold against commercially available human demineralized bone matrix approved for clinical use. Conclusion: We are unaware of any porcine-derived bone graft products currently used in orthopaedic surgery practice. Results from the current study suggest that porcine-derived bone scaffolds warrant further consideration to serve as a potential bone graft substitute.
- 12 July 2018
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 9 (3) , 45
Open AccessA Decellularized Porcine Xenograft-Derived Bone Scaffold for Clinical Use as a Bone Graft Substitute: A Critical Evaluation of Processing and Structure
Background: Bone grafts are used in approximately one half of all musculoskeletal surgeries. Autograft bone is the historic gold standard but is limited in supply and its harvest imparts significant morbidity to the patient. Alternative sources of bone graft include allografts, synthetics and, less commonly, xenografts which are taken from animal species. Xenografts are available in unlimited supply from healthy animal donors with controlled biology, avoiding the risk of human disease transmission, and may satisfy current demand for bone graft products. Methods: In the current study, cancellous bone was harvested from porcine femurs and subjected to a novel decellularization protocol to derive a bone scaffold. Results: The scaffold was devoid of donor cellular material on histology and DNA sampling (p < 0.01). Microarchitectural properties important for osteoconductive potential were preserved after decellularization as shown by high resolution imaging modalities. Proteomics data demonstrated similar profiles when comparing the porcine bone scaffold against commercially available human demineralized bone matrix approved for clinical use. Conclusion: We are unaware of any porcine-derived bone graft products currently used in orthopaedic surgery practice. Results from the current study suggest that porcine-derived bone scaffolds warrant further consideration to serve as a potential bone graft substitute.
- 27 September 2016
- Published by Wiley in Arthroscopy
- Vol. 33 (2) , 374-386
The Development of a Xenograft‐Derived Scaffold for Tendon and Ligament Reconstruction Using a Decellularization and Oxidation Protocol
Purpose: To evaluate the biological, immunological, and biomechanical properties of a scaffold derived by architectural modification of a fresh‐frozen porcine patella tendon using a decellularization protocol that combines physical, chemical, and enzymatic modalities. Methods: Porcine patellar tendons were processed using a decellularization and oxidation protocol that combines physical, chemical, and enzymatic modalities. Scaffolds (n = 88) were compared with native tendons (n = 70) using histologic, structural (scanning electron microscopy, porosimetry, and tensile testing), biochemical (mass spectrometry, peracetic acid reduction, DNA quantification, alpha‐galactosidase [α‐gal] content), as well as in vitro immunologic (cytocompatibility, cytokine induction) and in vivo immunologic nonhuman primate analyses. Results: A decrease in cellularity based on histology and a significant decrease in DNA content were observed in the scaffolds compared with the native tendon ( P < .001). Porosity and pore size were increased significantly ( P < .001). Scaffolds were cytocompatible in vitro. There was no difference between native tendons and scaffolds when comparing ultimate tensile load, stiffness, and elastic modulus. The α‐gal xenoantigen level was significantly lower in the decellularized scaffold group compared with fresh‐frozen, nondecellularized tissue ( P < .001). The in vivo immunological response to implanted scaffolds measured by tumor necrosis factor‐α and interleukin‐6 levels was significantly ( P < .001) reduced compared with untreated controls in vitro. These results were confirmed by an attenuated response to scaffolds in vivo after implantation in a nonhuman primate model. Conclusions: Porcine tendon was processed via a method of decellularization and oxidation to produce a scaffold that possessed significantly less inflammatory potential than a native tendon, was biocompatible in vitro, of increased porosity, and with significantly reduced amounts of α‐gal epitope while retaining tensile properties. Clinical Relevance: Porcine‐derived scaffolds may provide a readily available source of material for musculoskeletal reconstruction and repair while eliminating concerns regarding disease transmission and the morbidity of autologous harvest.
- 27 September 2016
- Published by Wiley in Arthroscopy
- Vol. 33 (2) , 374-386
The Development of a Xenograft‐Derived Scaffold for Tendon and Ligament Reconstruction Using a Decellularization and Oxidation Protocol
Purpose: To evaluate the biological, immunological, and biomechanical properties of a scaffold derived by architectural modification of a fresh‐frozen porcine patella tendon using a decellularization protocol that combines physical, chemical, and enzymatic modalities. Methods: Porcine patellar tendons were processed using a decellularization and oxidation protocol that combines physical, chemical, and enzymatic modalities. Scaffolds (n = 88) were compared with native tendons (n = 70) using histologic, structural (scanning electron microscopy, porosimetry, and tensile testing), biochemical (mass spectrometry, peracetic acid reduction, DNA quantification, alpha‐galactosidase [α‐gal] content), as well as in vitro immunologic (cytocompatibility, cytokine induction) and in vivo immunologic nonhuman primate analyses. Results: A decrease in cellularity based on histology and a significant decrease in DNA content were observed in the scaffolds compared with the native tendon ( P < .001). Porosity and pore size were increased significantly ( P < .001). Scaffolds were cytocompatible in vitro. There was no difference between native tendons and scaffolds when comparing ultimate tensile load, stiffness, and elastic modulus. The α‐gal xenoantigen level was significantly lower in the decellularized scaffold group compared with fresh‐frozen, nondecellularized tissue ( P < .001). The in vivo immunological response to implanted scaffolds measured by tumor necrosis factor‐α and interleukin‐6 levels was significantly ( P < .001) reduced compared with untreated controls in vitro. These results were confirmed by an attenuated response to scaffolds in vivo after implantation in a nonhuman primate model. Conclusions: Porcine tendon was processed via a method of decellularization and oxidation to produce a scaffold that possessed significantly less inflammatory potential than a native tendon, was biocompatible in vitro, of increased porosity, and with significantly reduced amounts of α‐gal epitope while retaining tensile properties. Clinical Relevance: Porcine‐derived scaffolds may provide a readily available source of material for musculoskeletal reconstruction and repair while eliminating concerns regarding disease transmission and the morbidity of autologous harvest.
- 29 September 2014
- Published by Springer Nature
- p. 1-14
Tissue-Engineered Approach to Tendon and Ligament Reconstruction: Current Trends
- 29 September 2014
- Published by Springer Nature
- p. 1-14
Tissue-Engineered Approach to Tendon and Ligament Reconstruction: Current Trends
- 1 January 2014
- Vol. 43 (1) , E19-24
A comparison of acetate and digital templating for hip resurfacing.
This study sought to determine whether templating for metal-on-metal hip resurfacing is more accurate with digital or acetate methodology. The medical records of 102 consecutive patients who underwent hip resurfacing at our institution were retrospectively reviewed. Records lacking preoperative radiographs that included a magnification-establishing marker were excluded, leaving 78 records for study. Two investigators independently prepared acetate and digital templates of the preoperative radiographs, which had been calibrated to 120% magnification, to predict femoral and acetabular component size. Accuracy was measured by comparing the predicted component sizes to the surgically implanted component sizes. Digital templating was more accurate than acetate templating in predicting hip resurfacing component size when measuring accuracy of templates by the absolute error of predicted component sizes (femoral, P < .001; acetabular, P = .002), and by the prediction of components to +/-1 size difference (femoral, P = .001; acetabular, P = .002). Experience of the templating surgeon did not correlate with templating accuracy for acetate or digital templating. Although acetate templating is often regarded as the "gold standard" in preoperative planning, data from the current study shows that digital technology can be used for accurate preoperative templating prior to hip resurfacing procedures.
- 1 January 2014
- Vol. 43 (1) , E19-24
A comparison of acetate and digital templating for hip resurfacing.
This study sought to determine whether templating for metal-on-metal hip resurfacing is more accurate with digital or acetate methodology. The medical records of 102 consecutive patients who underwent hip resurfacing at our institution were retrospectively reviewed. Records lacking preoperative radiographs that included a magnification-establishing marker were excluded, leaving 78 records for study. Two investigators independently prepared acetate and digital templates of the preoperative radiographs, which had been calibrated to 120% magnification, to predict femoral and acetabular component size. Accuracy was measured by comparing the predicted component sizes to the surgically implanted component sizes. Digital templating was more accurate than acetate templating in predicting hip resurfacing component size when measuring accuracy of templates by the absolute error of predicted component sizes (femoral, P < .001; acetabular, P = .002), and by the prediction of components to +/-1 size difference (femoral, P = .001; acetabular, P = .002). Experience of the templating surgeon did not correlate with templating accuracy for acetate or digital templating. Although acetate templating is often regarded as the "gold standard" in preoperative planning, data from the current study shows that digital technology can be used for accurate preoperative templating prior to hip resurfacing procedures.